Okami Medical Announces $45M Financing and Leadership Transition to Accelerate Commercialization of LOBO Vascular Occlusion Platform
Okami Medical
Medical Device Developer
Heart Future
Recently, focusing on the research and development of vascular embolization solutions,Okami Medical The company announced a double whammy: the successful completion of an oversubscribed $45 million (approximatelyRMB 320 million) Financing, at the same timeAppointment of Drew Hykes as President and CEO of the Company, Bill Hoffman as Chairman of the Board.
This round of financing and personnel adjustments will inject strong momentum into the commercial expansion of the company's core products and the advancement of its innovative pipeline.
# Financing Details: Led by Giants, Funds Focus on Commerce and R&D
This round of financing was led by new investorsGilde Healthcare Led by, existing investorsVensana Capital、U.S. Venture Partners Etc. actively follow-up investments.
It is worth noting that,This was completed by the company more than a year ago.3250 "Million USD"（Approximately RMB2.3Hundred Million）Additional Rounds After Financing`, highlighting the capital market's high recognition of its technical strength and market potential.`
As an important component of financing,Gilde Healthcare TheGeoff Pardo AndSusana Amorim Will joinOkami Medical Board of Directors.
Expand commercial layout, enhance product market penetration;
Advance Clinical Programs Related to Vascular Disease Treatment;
Continuously support the innovative R&D of peripheral vascular occlusion devices, including core products.LOBO Series.
# Personnel Changes: Industry Veteran Takes the Helm, Empowering Strategic Upgrade
New President andCEO Drew Hykes A senior operations manager in the medical device field, with extensive experience across functions, regions, and multiple domains.
Drew Hykes Professional Resume
2023 To2025 During the year, DrewHykes Serve asInari Medical Chief Executive Officer, successfully led the company to be acquired by Stryker for approximately50 Billion-dollar acquisition.
2020 To2022 Yearly AppointmentInari Medical Chief Operating Officer, responsible for daily business operations;2017 To2019 Served as the company's Chief Commercial Officer in [Year].
Previously,Drew HykesYu2012 To2016 Year inSequent Medical Serve as Vice President of Commercial Operations, leadingWEB The commercialization strategy of the aneurysm embolization system, from early prototypes to widespread use in the European market, was later implemented by2016 Year acquired by Terumo for3.8 Billion-dollar acquisition.
Earlier, he worked at Medtronic. 11 Years, served as Vice President of Marketing for the Atrial Fibrillation Solutions business, Vice President of Clinical and Regulatory Affairs, and Director of Investor Relations, during which time he was stationed in Europe.3Year, led the launch of Medtronic's first drug-eluting coronary stent.
Drew Hykes Representation："JoinOkami The team makes me feel deeply honored.LOBO The clinical performance and adaptability of the vascular occluder across various vascular anatomies have impressed me. I look forward to collaborating with this outstanding team to accelerate commercial expansion, advance the innovative R&D pipeline, and bring this vital technology to more doctors and patients."
# Core Products:LOBO Vascular OcclusionDevice, Reshaping Peripheral Vascular Occlusion Treatment
Okami Medical The core product isLOBO(Low Profile Braided Occluder) Vascular Occlusion System, accompanying products includeSendero Microcatheter, all have been obtainedFDA Approval.
Low Aperture Design:Pore Density of LOBO OccluderFour times higher than other weaving methods, with smaller poresThis significantly helps reduce blood flow, accelerating hemostasis and thrombosis. Utilizing proprietary HDBRAID technology—an innovative braiding method specifically developed for manufacturing vascular occlusion devices. Using this technique, braided devices can be made with wires smaller than 20 microns in diameter—only one-fourth the thickness of a hair.
Multi-functional Design:Three-disc design enhances the shielding effect of HDBRAID technology; exhibits excellent trackability in small and tortuous vessels; provides efficient occlusion capabilities adaptable to various curved vessels.
Multi-disc Design:This design enhances the sealing effect,Provides a dense pore structure across the vascular lumen., laying the foundation for effective treatment.
One-touch mechanical separation:The occluder can be accurately and immediately released at the target position, improving the efficiency and safety of the surgery.
User-Friendly:LOBO System is compatible with thin microcatheters,Can occlude vessels as small as 1.5mm, with a visualized radiopaque marker band for easy positioning and retrieval during surgery.
The development of the LOBO system provides interventional physicians with a single-device, one-time solution for occluding various peripheral arterial targets, eliminating the need for multiple embolic devices, thereby simplifying the surgical process and enhancing treatment outcomes.
Sendero Developed by Okami Medical®A microcatheter is a specialized microcatheter designed for the peripheral vascular system, used to deliver diagnostic and therapeutic agents.
Sendero®The design takes user-friendliness into account and has the following features:
LowFrictionConveyance：Smooth PTFE (Polytetrafluoroethylene) Lining for low-friction delivery，Microcatheters can easily navigate within blood vessels.
Movement. And it can reduce the damage and irritation to the surrounding tissue when the instrument is inserted and removed. Distal Flexibility, Proximal Support:Catheter The distal end has high flexibility. , so that it can smoothly pass through the bends and branches of blood vessels, reducing damage to the vessel walls and also lowering the risk of complications during the surgical procedure. The catheter's Proximal support is sufficient. , so that the doctor can apply force to push the catheter forward. Stainless Steel Braiding:Increased the strength and pushability of the microcatheter., ensuring stability in complex vascular pathways.
Accurate Placement: The transition design and braiding structure of the catheter are crucial for the precise placement of interventional devices within blood vessels. Product Design Ensure good navigation performance of the catheter within the blood vessel , while providing the required pushing force and support, Helps ensure smooth transition of the catheter within the blood vessel . The braided structure can Provides excellent torque transmission and push performance ， Enables doctors to precisely control the movement and rotation of the catheter.
Sendero®Has received U.S. FDA 510(k) clearance, indicating that its safety and effectiveness have been recognized. It is specifically designed for the LOBO system.Designed to assist in the delivery of LOBO-3 and LOBO-5 occluders, which are suitable for vascular occlusion of different diameters.
# Company Introduction: Focusing on Peripheral Vascular Innovation to Meet Unmet Clinical Needs
The team at Okami Medical has over a decade of leadership experience in the fields of braiding technology and minimally invasive vascular solutions.The company has garnered support from its board members, USVP (U.S. Venture Partners), and seasoned veterans of the medical device industry.
In the future, under the leadership of the new management team and with the support of a new round of financing,Okami Medical Expected to further expand its market influence in the field of vascular intervention, promoting innovative technologies to benefit more patients.
GCC2025
Cardiovascular Device Full Disease Solution
Statement
Content Declaration:"Future of the Heart" tracks global medical technology advancements, aiming to disseminate technical and industrial knowledge. All content is intended for industry exchange and academic discussion, and does not constitute medical advice or commercial promotion. Information regarding companies, products, and registrations mentioned in the text is sourced from publicly available materials or verified channels. If there are any errors or omissions, please feel free to contact us for corrections. Email: jacky@suribot.com
Copyright Statement:The original article "Heart Future" is copyrighted by Beijing Siyu Bot Technology Co., Ltd. Without authorization, it cannot be reproduced, excerpted, or mirrored on other websites, WeChat Official Accounts, or commercial platforms. For reprinting, please contact the backend to obtain authorization. This platform reserves the right to pursue legal responsibility for unauthorized full-text reproduction, rewriting, or paraphrasing.
